Amphastar Pharmaceuticals Reports Net Revenues of $56.9 Million for the First Quarter Ended March 31, 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Jefferies Remains Bullish Following Amphastar Pharma's (AMPH) Strong Q1
May 14, 2015 10:27 AM EDTJefferies maintains a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), and raised the price target to $19.00 (from $18.00), after a strong Q1. Analyst David Steinberg said that the strong Q1 was driven by a better than expected top line.
Steinberg commented on AMPH, saying, "Posting sales of $27.1M (+37% Y/Y), AMPHs base IMS injectables business contributed to half of the Q1 rev upside relative to our est, largely reflecting price... More
Amphastar Pharma (AMPH) Reports Q1 Loss of 1c/Share
May 13, 2015 6:01 AM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of ($0.01), versus $0.00 reported last year. Revenue for the quarter came in at $56.89 million, versus $45.87 million reported last year.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More